MXPA06013709A - Ligandos fijadores del complejo activador de plasminogeno de tipo uroquinasa (upa) y su receptor (upar), que inhiben las interacciones de upar corriente abajo: identificacion y uso en diagnostico o en terapia. - Google Patents

Info

Publication number

MXPA06013709A

MXPA06013709A MXPA06013709A MXPA06013709A MXPA06013709A MX PA06013709 A MXPA06013709 A MX PA06013709A MX PA06013709 A MXPA06013709 A MX PA06013709A MX PA06013709 A MXPA06013709 A MX PA06013709A MX PA06013709 A MXPA06013709 A MX PA06013709A

Authority

MX

Mexico

Prior art keywords

ligand

binding

upar

upa

atn

Prior art date

2004-05-25

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003446 ligand Substances 0.000 title claims abstract description 113
• 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 title claims abstract 12
• 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 title claims abstract 12
• 230000027455 binding Effects 0.000 title claims description 156
• 238000003745 diagnosis Methods 0.000 title claims description 25
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims description 12
• 230000003993 interaction Effects 0.000 title abstract description 18
• 238000002560 therapeutic procedure Methods 0.000 title abstract description 9
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title description 4
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 90
• 102000006495 integrins Human genes 0.000 claims abstract description 17
• 108010044426 integrins Proteins 0.000 claims abstract description 17
• 210000004027 cell Anatomy 0.000 claims description 188
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 113
• 238000000034 method Methods 0.000 claims description 88
• 239000012634 fragment Substances 0.000 claims description 68
• 239000000427 antigen Substances 0.000 claims description 60
• 108091007433 antigens Proteins 0.000 claims description 59
• 102000036639 antigens Human genes 0.000 claims description 59
• 150000001875 compounds Chemical class 0.000 claims description 56
• 238000004458 analytical method Methods 0.000 claims description 54
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
• 150000001413 amino acids Chemical class 0.000 claims description 32
• 230000001225 therapeutic effect Effects 0.000 claims description 31
• 229920001184 polypeptide Polymers 0.000 claims description 30
• 230000033115 angiogenesis Effects 0.000 claims description 29
• 210000004408 hybridoma Anatomy 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 28
• 150000007523 nucleic acids Chemical class 0.000 claims description 22
• 206010027476 Metastases Diseases 0.000 claims description 21
• 230000009401 metastasis Effects 0.000 claims description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims description 20
• 108020004707 nucleic acids Proteins 0.000 claims description 19
• 102000039446 nucleic acids Human genes 0.000 claims description 19
• 239000000126 substance Substances 0.000 claims description 17
• 230000004614 tumor growth Effects 0.000 claims description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
• 238000002347 injection Methods 0.000 claims description 12
• 239000007924 injection Substances 0.000 claims description 12
• 201000010099 disease Diseases 0.000 claims description 11
• 230000012292 cell migration Effects 0.000 claims description 10
• 108700012359 toxins Proteins 0.000 claims description 9
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
• 108091034117 Oligonucleotide Proteins 0.000 claims description 8
• 230000002401 inhibitory effect Effects 0.000 claims description 8
• 239000003053 toxin Substances 0.000 claims description 8
• 231100000765 toxin Toxicity 0.000 claims description 8
• 230000000259 anti-tumor effect Effects 0.000 claims description 7
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 7
• 230000004663 cell proliferation Effects 0.000 claims description 6
• 230000006957 competitive inhibition Effects 0.000 claims description 6
• 230000008878 coupling Effects 0.000 claims description 6
• 238000010168 coupling process Methods 0.000 claims description 6
• 238000005859 coupling reaction Methods 0.000 claims description 6
• 230000012010 growth Effects 0.000 claims description 6
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 6
• 230000001772 anti-angiogenic effect Effects 0.000 claims description 5
• 239000002246 antineoplastic agent Substances 0.000 claims description 5
• 230000004709 cell invasion Effects 0.000 claims description 5
• 230000001404 mediated effect Effects 0.000 claims description 5
• 108091023037 Aptamer Proteins 0.000 claims description 4
• 108010031318 Vitronectin Proteins 0.000 claims description 4
• 102100035140 Vitronectin Human genes 0.000 claims description 4
• 230000006907 apoptotic process Effects 0.000 claims description 4
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims description 4
• ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 claims description 4
• ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 claims description 4
• VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 claims description 3
• 108010067306 Fibronectins Proteins 0.000 claims description 3
• 108010053210 Phycocyanin Proteins 0.000 claims description 3
• 108010004729 Phycoerythrin Proteins 0.000 claims description 3
• 108010004469 allophycocyanin Proteins 0.000 claims description 3
• 208000035475 disorder Diseases 0.000 claims description 3
• 239000012216 imaging agent Substances 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 238000012879 PET imaging Methods 0.000 claims description 2
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 2
• 229940044683 chemotherapy drug Drugs 0.000 claims description 2
• 230000009137 competitive binding Effects 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 14
• 102100037362 Fibronectin Human genes 0.000 claims 2
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 113
• 102000004169 proteins and genes Human genes 0.000 abstract description 58
• 201000011510 cancer Diseases 0.000 abstract description 25
• 238000002405 diagnostic procedure Methods 0.000 abstract description 2
• 235000018102 proteins Nutrition 0.000 description 51
• 230000014509 gene expression Effects 0.000 description 42
• 239000000523 sample Substances 0.000 description 37
• 239000013598 vector Substances 0.000 description 28
• 238000011282 treatment Methods 0.000 description 25
• 241001465754 Metazoa Species 0.000 description 23
• 108020004414 DNA Proteins 0.000 description 22
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
• 239000002953 phosphate buffered saline Substances 0.000 description 22
• 210000004881 tumor cell Anatomy 0.000 description 22
• 238000012360 testing method Methods 0.000 description 21
• 238000001727 in vivo Methods 0.000 description 19
• 239000003814 drug Substances 0.000 description 18
• 108010082117 matrigel Proteins 0.000 description 18
• 239000007787 solid Substances 0.000 description 18
• 238000013508 migration Methods 0.000 description 17
• -1 phosphoribosyl Chemical group 0.000 description 17
• 239000002299 complementary DNA Substances 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 230000005012 migration Effects 0.000 description 16
• 210000001519 tissue Anatomy 0.000 description 16
• 238000004519 manufacturing process Methods 0.000 description 15
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
• 102000004190 Enzymes Human genes 0.000 description 14
• 108090000790 Enzymes Proteins 0.000 description 14
• 238000013459 approach Methods 0.000 description 14
• 229940088598 enzyme Drugs 0.000 description 14
• 238000003018 immunoassay Methods 0.000 description 14
• 239000002609 medium Substances 0.000 description 14
• 239000012528 membrane Substances 0.000 description 14
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 238000001514 detection method Methods 0.000 description 13
• 210000004379 membrane Anatomy 0.000 description 13
• 239000003112 inhibitor Substances 0.000 description 12
• 210000002889 endothelial cell Anatomy 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 235000002639 sodium chloride Nutrition 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 10
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 description 10
• 239000002585 base Substances 0.000 description 10
• 201000000050 myeloid neoplasm Diseases 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 241001529936 Murinae Species 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 230000001580 bacterial effect Effects 0.000 description 9
• 238000010276 construction Methods 0.000 description 9
• 230000002068 genetic effect Effects 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• 210000004962 mammalian cell Anatomy 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 206010003571 Astrocytoma Diseases 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 239000003242 anti bacterial agent Substances 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000013595 glycosylation Effects 0.000 description 8
• 238000006206 glycosylation reaction Methods 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• 239000006228 supernatant Substances 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 7
• 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 7
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
• 229940088710 antibiotic agent Drugs 0.000 description 7
• 229940098773 bovine serum albumin Drugs 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 238000010790 dilution Methods 0.000 description 7
• 239000012895 dilution Substances 0.000 description 7
• 238000011156 evaluation Methods 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 239000010410 layer Substances 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 108020004999 messenger RNA Proteins 0.000 description 7
• 230000008488 polyadenylation Effects 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 238000006467 substitution reaction Methods 0.000 description 7
• 230000008685 targeting Effects 0.000 description 7
• 230000000699 topical effect Effects 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 206010009944 Colon cancer Diseases 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 238000007796 conventional method Methods 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 210000003527 eukaryotic cell Anatomy 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 210000005260 human cell Anatomy 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 229910052751 metal Inorganic materials 0.000 description 6
• 239000002184 metal Substances 0.000 description 6
• 239000002674 ointment Substances 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 230000002588 toxic effect Effects 0.000 description 6
• 238000005406 washing Methods 0.000 description 6
• 206010016654 Fibrosis Diseases 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 206010033128 Ovarian cancer Diseases 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 230000002491 angiogenic effect Effects 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 230000009400 cancer invasion Effects 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 235000014633 carbohydrates Nutrition 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 231100000433 cytotoxic Toxicity 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• 230000004761 fibrosis Effects 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 230000002163 immunogen Effects 0.000 description 5
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 108010078791 Carrier Proteins Proteins 0.000 description 4
• 229920002307 Dextran Polymers 0.000 description 4
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
• 206010029113 Neovascularisation Diseases 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 108010058846 Ovalbumin Proteins 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 229920001213 Polysorbate 20 Polymers 0.000 description 4
• 235000004443 Ricinus communis Nutrition 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 239000005090 green fluorescent protein Substances 0.000 description 4
• 229960002897 heparin Drugs 0.000 description 4
• 229920000669 heparin Polymers 0.000 description 4
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 230000009545 invasion Effects 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 201000005296 lung carcinoma Diseases 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 206010061289 metastatic neoplasm Diseases 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 229940092253 ovalbumin Drugs 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
• 238000001243 protein synthesis Methods 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 210000003370 receptor cell Anatomy 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 206010003445 Ascites Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 102000003952 Caspase 3 Human genes 0.000 description 3
• 108090000397 Caspase 3 Proteins 0.000 description 3
• 102000012422 Collagen Type I Human genes 0.000 description 3
• 108010022452 Collagen Type I Proteins 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 108010073385 Fibrin Proteins 0.000 description 3
• 102000009123 Fibrin Human genes 0.000 description 3
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108091092195 Intron Proteins 0.000 description 3
• 108090001090 Lectins Proteins 0.000 description 3
• 102000004856 Lectins Human genes 0.000 description 3
• 102000011965 Lipoprotein Receptors Human genes 0.000 description 3
• 108010061306 Lipoprotein Receptors Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 3
• 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 210000002469 basement membrane Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 239000003593 chromogenic compound Substances 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 230000002860 competitive effect Effects 0.000 description 3
• 210000004087 cornea Anatomy 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000001962 electrophoresis Methods 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 229950003499 fibrin Drugs 0.000 description 3
• 239000000834 fixative Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 208000005017 glioblastoma Diseases 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• 238000011503 in vivo imaging Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 238000007917 intracranial administration Methods 0.000 description 3
• 239000002523 lectin Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 150000002739 metals Chemical class 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 238000011580 nude mouse model Methods 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 239000013600 plasmid vector Substances 0.000 description 3
• 229920002401 polyacrylamide Polymers 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 230000009257 reactivity Effects 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000000472 traumatic effect Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 231100000699 Bacterial toxin Toxicity 0.000 description 2
• 101001011741 Bos taurus Insulin Proteins 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• 108010053187 Diphtheria Toxin Proteins 0.000 description 2
• 102000016607 Diphtheria Toxin Human genes 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 201000009273 Endometriosis Diseases 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• 206010051814 Eschar Diseases 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 206010018341 Gliosis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• 102000000853 LDL receptors Human genes 0.000 description 2
• 108010001831 LDL receptors Proteins 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 230000004988 N-glycosylation Effects 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 201000010133 Oligodendroglioma Diseases 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 231100000742 Plant toxin Toxicity 0.000 description 2
• 102000013566 Plasminogen Human genes 0.000 description 2
• 108010051456 Plasminogen Proteins 0.000 description 2
• 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
• 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 2
• 108020005067 RNA Splice Sites Proteins 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 206010064390 Tumour invasion Diseases 0.000 description 2
• MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000011149 active material Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 230000006427 angiogenic response Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000005911 anti-cytotoxic effect Effects 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 239000000688 bacterial toxin Substances 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000005018 casein Substances 0.000 description 2
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
• 235000021240 caseins Nutrition 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 150000005829 chemical entities Chemical class 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 230000000536 complexating effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000002059 diagnostic imaging Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 231100000333 eschar Toxicity 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 230000007387 gliosis Effects 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 238000010166 immunofluorescence Methods 0.000 description 2
• 238000011532 immunohistochemical staining Methods 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 230000004899 motility Effects 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
• 230000013152 negative regulation of cell migration Effects 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 206010073131 oligoastrocytoma Diseases 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 210000003200 peritoneal cavity Anatomy 0.000 description 2
• 239000003123 plant toxin Substances 0.000 description 2
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
• 238000003752 polymerase chain reaction Methods 0.000 description 2
• 229920002223 polystyrene Polymers 0.000 description 2
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 125000006853 reporter group Chemical group 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 108700026220 vif Genes Proteins 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229940075420 xanthine Drugs 0.000 description 2
• KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
• FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• ZXXTYLFVENEGIP-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurine-2,6-dione Chemical compound O=C1NC(N)=NC2=C1NC=N2.O=C1NC(=O)NC2=C1NC=N2 ZXXTYLFVENEGIP-UHFFFAOYSA-N 0.000 description 1
• BNBQQYFXBLBYJK-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-oxazole Chemical class C1=COC(C=2N=CC=CC=2)=N1 BNBQQYFXBLBYJK-UHFFFAOYSA-N 0.000 description 1
• OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
• AWKYSZSJPJUFQS-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1NC(=O)NC2=C1NC=N2 AWKYSZSJPJUFQS-UHFFFAOYSA-N 0.000 description 1
• APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
• VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010080691 Alcohol O-acetyltransferase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 108010042086 Collagen Type IV Proteins 0.000 description 1
• 102000004266 Collagen Type IV Human genes 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 229920002271 DEAE-Sepharose Polymers 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 241000255601 Drosophila melanogaster Species 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 241000305071 Enterobacterales Species 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000006830 Luminescent Proteins Human genes 0.000 description 1
• 108010047357 Luminescent Proteins Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• 208000034827 Neointima Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 101150044441 PECAM1 gene Proteins 0.000 description 1
• 101150038998 PLAUR gene Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
• 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 101000760333 Rattus norvegicus Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 240000000528 Ricinus communis Species 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 108050000761 Serpin Proteins 0.000 description 1
• 102000008847 Serpin Human genes 0.000 description 1
• 241000607715 Serratia marcescens Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000001662 Subependymal Glioma Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 108090000054 Syndecan-2 Proteins 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 208000016599 Uterine disease Diseases 0.000 description 1
• 206010049060 Vascular Graft Occlusion Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010073696 Wallerian degeneration Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 239000005083 Zinc sulfide Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229940067621 aminobutyrate Drugs 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 239000002269 analeptic agent Substances 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 208000014534 anaplastic ependymoma Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• GQKVCZAPFYNZHX-UHFFFAOYSA-N anthracene-2,3-dicarboxylic acid Chemical compound C1=CC=C2C=C(C=C(C(C(=O)O)=C3)C(O)=O)C3=CC2=C1 GQKVCZAPFYNZHX-UHFFFAOYSA-N 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001740 anti-invasion Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002095 anti-migrative effect Effects 0.000 description 1
• 230000002141 anti-parasite Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940124536 anticoccidial agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 229960005475 antiinfective agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000003096 antiparasitic agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 238000011717 athymic nude mouse Methods 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• QCUOBSQYDGUHHT-UHFFFAOYSA-L cadmium sulfate Chemical compound [Cd+2].[O-]S([O-])(=O)=O QCUOBSQYDGUHHT-UHFFFAOYSA-L 0.000 description 1
• 229910000331 cadmium sulfate Inorganic materials 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000003224 coccidiostatic agent Substances 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000006482 condensation reaction Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 208000021921 corneal disease Diseases 0.000 description 1
• 201000000159 corneal neovascularization Diseases 0.000 description 1
• 150000001893 coumarin derivatives Chemical class 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
• 229940093541 dicetylphosphate Drugs 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000000437 effect on angiogenesis Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000001917 fluorescence detection Methods 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 102000005396 glutamine synthetase Human genes 0.000 description 1
• 108020002326 glutamine synthetase Proteins 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 101150106093 gpt gene Proteins 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 239000011147 inorganic material Substances 0.000 description 1
• 235000013902 inosinic acid Nutrition 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical group NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 229910052747 lanthanoid Inorganic materials 0.000 description 1
• 150000002602 lanthanoids Chemical class 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 238000010232 migration assay Methods 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 230000009149 molecular binding Effects 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 238000004264 monolayer culture Methods 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 201000004057 myxopapillary ependymoma Diseases 0.000 description 1
• KHARCSTZAGNHOT-UHFFFAOYSA-L naphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C=C(C([O-])=O)C(C(=O)[O-])=CC2=C1 KHARCSTZAGNHOT-UHFFFAOYSA-L 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 230000008692 neointimal formation Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960003330 pentetic acid Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 108010049224 perlecan Proteins 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000003504 photosensitizing agent Substances 0.000 description 1
• 229950001030 piritrexim Drugs 0.000 description 1
• 230000028742 placenta development Effects 0.000 description 1
• 230000033885 plasminogen activation Effects 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 108700028325 pokeweed antiviral Proteins 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000002046 pro-migratory effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 231100000654 protein toxin Toxicity 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 150000003220 pyrenes Chemical class 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001957 retinal vein Anatomy 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 239000007320 rich medium Substances 0.000 description 1
• 239000012488 sample solution Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 150000003346 selenoethers Chemical class 0.000 description 1
• 239000004054 semiconductor nanocrystal Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000003001 serine protease inhibitor Substances 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017550 sodium carbonate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 208000030819 subependymoma Diseases 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 229920003002 synthetic resin Polymers 0.000 description 1
• 239000000057 synthetic resin Substances 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
• 230000001173 tumoral effect Effects 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 230000006490 viral transcription Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 230000008734 wallerian degeneration Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 1